Biogen Inc. and Ultragenyx Pharmaceutical Inc.: SG&A Spending Patterns Compared

Biogen vs. Ultragenyx: A Decade of SG&A Spending Trends

__timestampBiogen Inc.Ultragenyx Pharmaceutical Inc.
Wednesday, January 1, 2014223234200010811000
Thursday, January 1, 2015211310000033001000
Friday, January 1, 2016194790000064936000
Sunday, January 1, 2017193550000099909000
Monday, January 1, 20182106300000127724000
Tuesday, January 1, 20192374700000161524000
Wednesday, January 1, 20202504500000182933000
Friday, January 1, 20212674300000219982000
Saturday, January 1, 20222403600000278139000
Sunday, January 1, 20232549700000309799000
Monday, January 1, 20242403700000
Loading chart...

Data in motion

SG&A Spending Patterns: Biogen Inc. vs. Ultragenyx Pharmaceutical Inc.

In the ever-evolving pharmaceutical industry, understanding spending patterns is crucial for strategic planning. Biogen Inc. and Ultragenyx Pharmaceutical Inc. offer a fascinating case study in contrasting approaches to Selling, General, and Administrative (SG&A) expenses over the past decade.

From 2014 to 2023, Biogen's SG&A expenses have shown a steady increase, peaking in 2021 with a 38% rise from 2014. In contrast, Ultragenyx's SG&A expenses have skyrocketed, increasing nearly 28 times over the same period. This dramatic growth reflects Ultragenyx's aggressive expansion strategy, while Biogen's more stable spending suggests a focus on maintaining its established market position.

These trends highlight the diverse strategies within the pharmaceutical sector, where established giants and emerging innovators navigate their paths to success. As the industry continues to evolve, monitoring these financial patterns will be key to understanding future market dynamics.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025